Concepedia

Paul V. Rucker

PV

Statistics

Publications

16

Citations

882

H-Index

16

Active since

1996

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

Pfizer (United States)

Novartis (United States)

Albert Einstein College of Medicine

University of California, Irvine

Paul V. Rucker is an author at Genomics Institute of the Novartis Research Foundation specializing in pharmacology, drug discovery, and pharmacy.

Publications per year

1996–2020

16

Publications

16

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

David C. Tully, Paul V. Rucker, D. CHIANELLI et al. · Journal of Medicinal Chemistry · 2017 · 230 citations · Full text

, , +17

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis

D. CHIANELLI, Paul V. Rucker, Jason Roland et al. · Journal of Medicinal Chemistry · 2020 · 99 citations · Full text

, , +16

Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents

Eloy D. Hernandez, Lianxing Zheng, Young Ho Kim et al. · Hepatology Communications · 2019 · 92 citations · Full text

, , +16

Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase

Shaun R. Selness, Rajesh Devraj, Balekudru Devadas et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 72 citations · Full text

, , +11

(<i>R</i>)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors

Ha-Soon Choi, Paul V. Rucker, Zhicheng Wang et al. · ACS Medicinal Chemistry Letters · 2015 · 62 citations · Full text

, , +13

1–5 of 16